Opconvision: Announcement on Obtaining the "Drug Production License"
Securities code: 300595 Securities abbreviation: Opcon Vision Announcement number: 2026-002
Opcon Vision Technology Co., Ltd.
Announcement on Obtaining the "Drug Production License"
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Opcom Vision Technology Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Production License" issued by the Anhui Provincial Food and Drug Administration. The specific situation is now announced as follows:
1. Basic information of "Drug Production License"
Company name: Opcom Vision Technology Co., Ltd.
Unified social credit code: 91340100723323559X
Address (business place): No. 4899, Wangjiang West Road, High-tech Zone, Hefei City
License number: Anhui 20250658
Classification code: Ah
Legal representative: Tao Yuequn
Person in charge of the enterprise: Wang Diankuo
Quality manager: Hao Zhanfei
Production manager: Chen Ping
Quality authorized person: Hao Zhanfei
Production address and production scope: No. 4899, Wangjiang West Road, High-tech Zone, Hefei City: Eye Drops (Note: No drug GMP compliance inspection has been conducted, and it is limited to registration and application use)
Valid until: December 25, 2030
Visa authority: Anhui Provincial Food and Drug Administration
2. Impact on the company and risk warning
This is the first time that the company has obtained the "Drug Production License", which is conducive to optimizing the company's product structure and has a positive role in promoting the company's long-term development. The company must pass the regulatory procedures such as product registration application, on-site inspection and drug GMP compliance inspection, and obtain the "Drug Registration Certificate" before it can be put on the market for commercial production and sales. Obtaining the "Drug Production License" will not have a significant impact on the company's operating performance in the short term.
Due to the industry characteristics of pharmaceutical products, future production and sales are affected by industry policies, market environment and other factors, and are uncertain. The company will fulfill its information disclosure obligations in a timely manner and strictly in accordance with relevant regulations. Investors are advised to pay attention to investment risks.
3. Documents for reference
"Drug Production License"
Announcement is hereby made.
Board of Directors of Opcon Vision Technology Co., Ltd.
January 5, 2026